Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Go back to Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 240.98 -2.12 (0.87%)
Previous Close $243.10    52 Week High $333.65 
Open $242.02    52 Week Low $223.02 
Day High $243.32    P/E 30.86 
Day Low $240.13    EPS $7.81 
Volume 812,898       

(NASDAQ: STOK) Delayed: 25.68 -0.93 (3.49%)
Previous Close $26.61    52 Week High $ 
Open $26.83    52 Week Low $ 
Day High $27.22    P/E N/A 
Day Low $25.31    EPS $ 
Volume 2,257,815